纳入多项正在进行的贝叶斯二阶段II期单臂研究的数据。

IF 2.2 3区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
Susan Halabi, Taehwa Choi, Elizabeth Garrett-Mayer, Richard L Schilsky, Lorenzo Trippa
{"title":"纳入多项正在进行的贝叶斯二阶段II期单臂研究的数据。","authors":"Susan Halabi, Taehwa Choi, Elizabeth Garrett-Mayer, Richard L Schilsky, Lorenzo Trippa","doi":"10.1177/17407745251358233","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>Basket designs have been utilized in recent oncology clinical trials due to an increased interest in precision medicine. One current successful basket trial is the American Society for Clinical Oncology Targeted Agent and Profiling Utilization Registry (TAPUR) study, a pragmatic phase II trial where patients are matched based on their tumor genomic profile to treatments that target specific genomic alterations. Despite its success, recruiting patients with rare genomic alterations remains challenging. This study aims to introduce and evaluate a Bayesian approach for integrating data from ongoing independent basket trials that share similar primary aims to improve interim decisions and final analyses and reduce necessary to evaluate treatments.</p><p><strong>Methods: </strong>We introduce a Bayesian two-stage phase II single-arm trial specifically for rare cancers utilizing a hierarchical Bayesian random effects model that incorporate data from ongoing trials. We compare this approach with the standard Simon two-stage design through extensive numerical simulations and apply it to real-world scenarios.</p><p><strong>Results: </strong>Simulation results demonstrate that in rare populations our Bayesian approach has attractive operating characteristics. The simulations show that our approach performs well across a broad set of scenarios with fixed and variable numbers of trials.</p><p><strong>Conclusion: </strong>Our proposed Bayesian two-stage approach effectively integrates data from multiple ongoing basket trials, enhancing the ability to recruit and analyze patients with rare genomic alterations. This approach improves the timing of interim decision-making and final analysis, making it a valuable tool for trials with slow accrual rates.</p>","PeriodicalId":10685,"journal":{"name":"Clinical Trials","volume":" ","pages":"17407745251358233"},"PeriodicalIF":2.2000,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12373003/pdf/","citationCount":"0","resultStr":"{\"title\":\"Incorporating data from multiple ongoing trials for Bayesian two-stage phase II single-arm studies.\",\"authors\":\"Susan Halabi, Taehwa Choi, Elizabeth Garrett-Mayer, Richard L Schilsky, Lorenzo Trippa\",\"doi\":\"10.1177/17407745251358233\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background/aim: </strong>Basket designs have been utilized in recent oncology clinical trials due to an increased interest in precision medicine. One current successful basket trial is the American Society for Clinical Oncology Targeted Agent and Profiling Utilization Registry (TAPUR) study, a pragmatic phase II trial where patients are matched based on their tumor genomic profile to treatments that target specific genomic alterations. Despite its success, recruiting patients with rare genomic alterations remains challenging. This study aims to introduce and evaluate a Bayesian approach for integrating data from ongoing independent basket trials that share similar primary aims to improve interim decisions and final analyses and reduce necessary to evaluate treatments.</p><p><strong>Methods: </strong>We introduce a Bayesian two-stage phase II single-arm trial specifically for rare cancers utilizing a hierarchical Bayesian random effects model that incorporate data from ongoing trials. We compare this approach with the standard Simon two-stage design through extensive numerical simulations and apply it to real-world scenarios.</p><p><strong>Results: </strong>Simulation results demonstrate that in rare populations our Bayesian approach has attractive operating characteristics. The simulations show that our approach performs well across a broad set of scenarios with fixed and variable numbers of trials.</p><p><strong>Conclusion: </strong>Our proposed Bayesian two-stage approach effectively integrates data from multiple ongoing basket trials, enhancing the ability to recruit and analyze patients with rare genomic alterations. This approach improves the timing of interim decision-making and final analysis, making it a valuable tool for trials with slow accrual rates.</p>\",\"PeriodicalId\":10685,\"journal\":{\"name\":\"Clinical Trials\",\"volume\":\" \",\"pages\":\"17407745251358233\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-08-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12373003/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Trials\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/17407745251358233\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Trials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17407745251358233","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

背景/目的:由于对精准医学的兴趣增加,篮子设计已被用于最近的肿瘤临床试验。目前一个成功的篮子试验是美国临床肿瘤学会靶向药物和谱分析使用注册(TAPUR)研究,这是一项实用的II期试验,根据患者的肿瘤基因组谱与靶向特定基因组改变的治疗相匹配。尽管取得了成功,但招募具有罕见基因组变异的患者仍然具有挑战性。本研究旨在介绍和评估一种贝叶斯方法,用于整合正在进行的独立篮子试验的数据,这些试验具有相似的主要目的,以改善中期决策和最终分析,并减少评估治疗的必要性。方法:我们引入了一项针对罕见癌症的贝叶斯两阶段II期单臂试验,利用分层贝叶斯随机效应模型纳入了正在进行的试验的数据。我们通过广泛的数值模拟将这种方法与标准Simon两阶段设计进行比较,并将其应用于现实世界的场景。结果:仿真结果表明,在稀有种群中,贝叶斯方法具有很好的操作特性。模拟表明,我们的方法在具有固定和可变试验次数的广泛场景中表现良好。结论:我们提出的贝叶斯两阶段方法有效地整合了多个正在进行的篮子试验的数据,增强了招募和分析罕见基因组改变患者的能力。这种方法改善了中期决策和最终分析的时间,使其成为具有缓慢应计率的试验的宝贵工具。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Incorporating data from multiple ongoing trials for Bayesian two-stage phase II single-arm studies.

Background/aim: Basket designs have been utilized in recent oncology clinical trials due to an increased interest in precision medicine. One current successful basket trial is the American Society for Clinical Oncology Targeted Agent and Profiling Utilization Registry (TAPUR) study, a pragmatic phase II trial where patients are matched based on their tumor genomic profile to treatments that target specific genomic alterations. Despite its success, recruiting patients with rare genomic alterations remains challenging. This study aims to introduce and evaluate a Bayesian approach for integrating data from ongoing independent basket trials that share similar primary aims to improve interim decisions and final analyses and reduce necessary to evaluate treatments.

Methods: We introduce a Bayesian two-stage phase II single-arm trial specifically for rare cancers utilizing a hierarchical Bayesian random effects model that incorporate data from ongoing trials. We compare this approach with the standard Simon two-stage design through extensive numerical simulations and apply it to real-world scenarios.

Results: Simulation results demonstrate that in rare populations our Bayesian approach has attractive operating characteristics. The simulations show that our approach performs well across a broad set of scenarios with fixed and variable numbers of trials.

Conclusion: Our proposed Bayesian two-stage approach effectively integrates data from multiple ongoing basket trials, enhancing the ability to recruit and analyze patients with rare genomic alterations. This approach improves the timing of interim decision-making and final analysis, making it a valuable tool for trials with slow accrual rates.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Clinical Trials
Clinical Trials 医学-医学:研究与实验
CiteScore
4.10
自引率
3.70%
发文量
82
审稿时长
6-12 weeks
期刊介绍: Clinical Trials is dedicated to advancing knowledge on the design and conduct of clinical trials related research methodologies. Covering the design, conduct, analysis, synthesis and evaluation of key methodologies, the journal remains on the cusp of the latest topics, including ethics, regulation and policy impact.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信